Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Numéro 10, Octobre 2005
Page(s) 825 - 831
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052110825
Publié en ligne 15 octobre 2005
  1. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91 : 4–15.
  2. George JN. Platelets. Lancet 2000; 355 : 1531–9.
  3. Martinez MC, Kunzelmann C, Freyssinet JM. Remodelage de la membrane plasmique et stimulation cellulaire. Med Sci (Paris) 2004; 20 : 189–95.
  4. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25 : 489–95.
  5. Fanslow WC, Srinivasan S, Paxton R, et al. Structural characteristics of CD40 ligand that determine biological function. Semin Immunol 1994; 6 : 267–78.
  6. Van Kooten C, Banchereau J. CD40-CD40 ligand. J Leuk Biol 2000; 67 : 2–17.
  7. Chan FK, Chun HJ, Zheng L, et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288 : 2351–4.
  8. Van Kooten C, Banchereau J. CD40-CD40 ligand: a multifunctional receptor-ligand pair. Adv Immunol 1996; 61 : 1–77.
  9. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-igM syndrome. J Pediatr 1997; 131 : 47–54.
  10. Kuwana M, Nomura S, Fujimura K, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood 2004; 103 : 1229–36.
  11. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391 : 591–4.
  12. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of t lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100 : 614–20.
  13. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res 2004; 114 : 167–77.
  14. Furman MI, Krueger LA, Linden MD, et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004; 43 : 2319–25.
  15. Solanilla A, Pasquet JM, Viallard JF, et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105 : 215–8.
  16. Pietravalle F, Lecoanet-Henchoz S, Blasey H, et al. Human native soluble CD40l is a biologically active trimer, processed inside microsomes. J Biol Chem 1996; 271 : 5965–7.
  17. Graf D, Muller S, Korthauer U, et al. A soluble form of trap (CD40 ligand) is rapidly released after t cell activation. Eur J Immunol 1995; 25 : 1749–54.
  18. Karpusas M, Hsu YM, Wang JH, et al. 2A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995; 3 : 1031–9.
  19. Weber AA, Hermann A, Rauch BH, Schror K. Molecular identity of platelet CD40 ligand (CD40l). Thromb Haemost 2001; 86 : 718.
  20. Henn V, Steinbach S, Buchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98 : 1047–54.
  21. Moss ML, Lambert MH. Shedding of membrane proteins by adam family proteases. Essays Biochem 2002; 38 : 141–53.
  22. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002; 99 : 2612–4.
  23. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391 : 591–4.
  24. Andre P, Prasad KS, Denis CV, et al. CD40l stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8 : 247–52.
  25. Lindmark E, Tenno T, Siegbahn A. Role of platelet p-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 2000; 20 : 2322–8.
  26. Slupsky JR, Kalbas M, Willuweit A, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80 : 1008–14.
  27. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates nf-kappa B and c-jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 2001; 166 : 6812–9.
  28. Tanaka T, Kuroiwa T, Ikeuchi H, et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol 2002; 13 : 2488–96.
  29. Lei XF, Ohkawara Y, Stampfli MR, et al. Disruption of antigen-induced inflammatory responses in CD40 ligand knockout mice. J Clin Invest 1998; 101 : 1342–53.
  30. May AE, Kalsch T, Massberg S, et al. Engagement of glycoprotein iib/iiia (alpha[iib]beta3) on platelets upregulates CD40l and triggers CD40l-dependent matrix degradation by endothelial cells. Circulation 2002; 106 : 2111–7.
  31. Czapiga M, Kirk AD, Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp Hematol 2004; 32 : 135–9.
  32. Elzey BD, Tian J, Jensen RJ, et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19 : 9–19.
  33. Prasad KS, Andre P, Yan Y, Phillips DR. The platelet CD40l/gp IIb-IIIa axis in atherothrombotic disease. Curr Opin Hematol 2003; 10 : 356–61.
  34. Buchner K, Henn V, Grafe M, et al. CD40 ligand is selectively expressed on CD4+ t cells and platelets: implications for CD40-CD40l signalling in atherosclerosis. J Pathol 2003; 201 : 288–95.
  35. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394 : 200–3.
  36. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5 : 1313–6.
  37. Reul RM, Fang JC, Denton MD, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 1997; 64 : 1765–74.
  38. Kirk AD, Harlan DM, Armstrong NN, et al. Ctla4-ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94 : 8789–94.
  39. Tamada K, Tamura H, Flies D, et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002; 109 : 549–57.
  40. Kalled SL, Cutler AH, Datta SK, Thomas DW. Anti-CD40 ligand antibody treatment of snf1 mice with established nephritis: preservation of kidney function. J Immunol 1998; 160 : 2158–65.
  41. Kairaitis L, Wang Y, Zheng L, et al. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int 2003; 64 : 1265–72.
  42. Ruth AJ, Kitching AR, Semple TJ, et al. Intrinsic renal cell expression of CD40 directs th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol 2003; 14 : 2813–22.
  43. Yellin MJ, D’Agati V, Parkinson G, et al. Immunohistologic analysis of renal CD40 and CD40l expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997; 40 : 124–34.
  44. Delmas Y, Viallard JF, Solanilla A, et al. Activation of mesangial cells by platelets in systemic lupus erythematosus via a CD154 dependent induction of CD40. Kidney Int 2005 (sous presse).

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.